Ascendis Pharma A/S (ASND) Competitors

$243.58 +5.93 (+2.50%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$244.07 +0.49 (+0.20%)

As of 04:06 AM Eastern

ASND vs. TAK, ARGX, TEVA, ONC, and RVMD

Should you buy Ascendis Pharma A/S stock or one of its competitors? MarketBeat compares Ascendis Pharma A/S with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ascendis Pharma A/S include Takeda Pharmaceutical (TAK), argenex (ARGX), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.

How does Ascendis Pharma A/S compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and Ascendis Pharma A/S (NASDAQ:ASND) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

In the previous week, Ascendis Pharma A/S had 7 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 13 mentions for Ascendis Pharma A/S and 6 mentions for Takeda Pharmaceutical. Ascendis Pharma A/S's average media sentiment score of 0.96 beat Takeda Pharmaceutical's score of -0.21 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Ascendis Pharma A/S has a consensus price target of $291.50, indicating a potential upside of 19.67%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.95

Ascendis Pharma A/S has a net margin of 57.87% compared to Takeda Pharmaceutical's net margin of 2.58%. Takeda Pharmaceutical's return on equity of 10.60% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	2.58%	10.60%	5.21%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Takeda Pharmaceutical has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market.

Takeda Pharmaceutical has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$30.09B	1.76	$712.33M	$0.24	69.27
Ascendis Pharma A/S	$865.78M	17.55	-$258M	$8.67	28.09

Summary

Ascendis Pharma A/S beats Takeda Pharmaceutical on 11 of the 17 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to argenex?

Ascendis Pharma A/S (NASDAQ:ASND) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

argenex has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$865.78M	17.55	-$258M	$8.67	28.09
argenex	$4.25B	11.75	$1.29B	$22.46	35.74

Ascendis Pharma A/S has a net margin of 57.87% compared to argenex's net margin of 31.31%. argenex's return on equity of 33.28% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
argenex	31.31%	33.28%	28.16%

Ascendis Pharma A/S presently has a consensus price target of $291.50, suggesting a potential upside of 19.67%. argenex has a consensus price target of $1,017.78, suggesting a potential upside of 26.79%. Given argenex's higher possible upside, analysts plainly believe argenex is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.95
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

60.3% of argenex shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 2.4% of argenex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, argenex had 14 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 27 mentions for argenex and 13 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.96 beat argenex's score of 0.79 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	7 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market. Comparatively, argenex has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

Summary

argenex beats Ascendis Pharma A/S on 12 of the 17 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to Teva Pharmaceutical Industries?

Ascendis Pharma A/S (NASDAQ:ASND) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

Teva Pharmaceutical Industries has higher revenue and earnings than Ascendis Pharma A/S. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$865.78M	17.55	-$258M	$8.67	28.09
Teva Pharmaceutical Industries	$17.35B	2.40	$1.41B	$1.33	27.26

Ascendis Pharma A/S has a net margin of 57.87% compared to Teva Pharmaceutical Industries' net margin of 9.01%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

Ascendis Pharma A/S presently has a consensus price target of $291.50, suggesting a potential upside of 19.67%. Teva Pharmaceutical Industries has a consensus price target of $41.78, suggesting a potential upside of 15.22%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, equities analysts plainly believe Ascendis Pharma A/S is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.95
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Ascendis Pharma A/S and Ascendis Pharma A/S both had 13 articles in the media. Ascendis Pharma A/S's average media sentiment score of 0.96 beat Teva Pharmaceutical Industries' score of 0.67 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market.

Summary

Ascendis Pharma A/S beats Teva Pharmaceutical Industries on 10 of the 16 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to BeOne Medicines?

Ascendis Pharma A/S (NASDAQ:ASND) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

In the previous week, BeOne Medicines had 3 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 16 mentions for BeOne Medicines and 13 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.96 beat BeOne Medicines' score of 0.51 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	3 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$865.78M	17.55	-$258M	$8.67	28.09
BeOne Medicines	$5.34B	6.50	$286.93M	$4.47	70.82

Ascendis Pharma A/S has a net margin of 57.87% compared to BeOne Medicines' net margin of 8.94%. BeOne Medicines' return on equity of 12.06% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
BeOne Medicines	8.94%	12.06%	6.69%

Ascendis Pharma A/S presently has a consensus target price of $291.50, suggesting a potential upside of 19.67%. BeOne Medicines has a consensus target price of $391.00, suggesting a potential upside of 23.52%. Given BeOne Medicines' higher probable upside, analysts clearly believe BeOne Medicines is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.95
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

Ascendis Pharma A/S has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

48.6% of BeOne Medicines shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 6.2% of BeOne Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

BeOne Medicines beats Ascendis Pharma A/S on 9 of the 16 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to Revolution Medicines?

Ascendis Pharma A/S (NASDAQ:ASND) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

In the previous week, Revolution Medicines had 7 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 20 mentions for Revolution Medicines and 13 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.96 beat Revolution Medicines' score of 0.19 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ascendis Pharma A/S has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$865.78M	17.55	-$258M	$8.67	28.09
Revolution Medicines	$11.58M	2,752.78	-$1.13B	-$7.07	N/A

Ascendis Pharma A/S has a net margin of 57.87% compared to Revolution Medicines' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Revolution Medicines	N/A	-83.22%	-59.06%

Ascendis Pharma A/S presently has a consensus target price of $291.50, suggesting a potential upside of 19.67%. Revolution Medicines has a consensus target price of $103.88, suggesting a potential downside of 30.72%. Given Ascendis Pharma A/S's higher probable upside, research analysts clearly believe Ascendis Pharma A/S is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.95
Revolution Medicines	1 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	3.10

Ascendis Pharma A/S has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

94.3% of Revolution Medicines shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 8.2% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Ascendis Pharma A/S beats Revolution Medicines on 11 of the 17 factors compared between the two stocks.

Get Ascendis Pharma A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASND vs. The Competition

Export

Metric	Ascendis Pharma A/S	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.82B	$3.42B	$6.30B	$12.20B
Dividend Yield	N/A	2.30%	2.79%	5.30%
P/E Ratio	28.09	18.67	21.03	25.58
Price / Sales	17.55	301.13	552.98	78.84
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	26.59	6.75	9.82	6.66
Net Income	-$258M	$24.11M	$3.55B	$333.63M
7 Day Performance	-1.04%	-0.53%	-0.53%	-0.11%
1 Month Performance	-2.51%	0.34%	1.20%	3.94%
1 Year Performance	54.95%	78.62%	41.23%	36.07%

Ascendis Pharma A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASND Ascendis Pharma A/S	3.8208 of 5 stars	$243.58 +2.5%	$291.50 +19.7%	+50.8%	$14.82B	$865.78M	28.09	1,189	Positive News Earnings Report Analyst Forecast Insider Trade
TAK Takeda Pharmaceutical	1.0322 of 5 stars	$16.34 -0.8%	N/A	+21.1%	$52.38B	$30.09B	68.07	47,455	News Coverage Gap Down
ARGX argenex	4.6438 of 5 stars	$813.28 +4.0%	$1,017.78 +25.1%	+48.0%	$48.64B	$4.25B	36.21	1,863	Earnings Report Analyst Revision
TEVA Teva Pharmaceutical Industries	4.092 of 5 stars	$35.91 +0.5%	$41.78 +16.3%	+107.4%	$41.08B	$17.26B	27.00	33,950
ONC BeOne Medicines	4.2747 of 5 stars	$310.75 -0.4%	$391.00 +25.8%	+40.9%	$34.25B	$5.74B	69.52	12,000	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASND) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ascendis Pharma A/S (ASND) Competitors

ASND vs. TAK, ARGX, TEVA, ONC, and RVMD

How does Ascendis Pharma A/S compare to Takeda Pharmaceutical?

Summary

How does Ascendis Pharma A/S compare to argenex?

Summary

How does Ascendis Pharma A/S compare to Teva Pharmaceutical Industries?

Summary

How does Ascendis Pharma A/S compare to BeOne Medicines?

Summary

How does Ascendis Pharma A/S compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASND vs. The Competition

Ascendis Pharma A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ascendis Pharma A/S (ASND) Competitors

ASND vs. TAK, ARGX, TEVA, ONC, and RVMD

How does Ascendis Pharma A/S compare to Takeda Pharmaceutical?

Does the media favor TAK or ASND?

Do insiders & institutionals have more ownership in TAK or ASND?

Do analysts prefer TAK or ASND?

Is TAK or ASND more profitable?

Which has more risk and volatility, TAK or ASND?

Which has higher valuation & earnings, TAK or ASND?

Summary

How does Ascendis Pharma A/S compare to argenex?

Which has higher earnings and valuation, ASND or ARGX?

Is ASND or ARGX more profitable?

Do analysts recommend ASND or ARGX?

Do institutionals & insiders have more ownership in ASND or ARGX?

Does the media refer more to ASND or ARGX?

Which has more risk and volatility, ASND or ARGX?

Summary

How does Ascendis Pharma A/S compare to Teva Pharmaceutical Industries?

Which has higher earnings and valuation, ASND or TEVA?

Is ASND or TEVA more profitable?

Do analysts recommend ASND or TEVA?

Do institutionals & insiders have more ownership in ASND or TEVA?

Does the media refer more to ASND or TEVA?

Which has more risk and volatility, ASND or TEVA?

Summary

How does Ascendis Pharma A/S compare to BeOne Medicines?

Does the media prefer ASND or ONC?

Which has stronger earnings & valuation, ASND or ONC?

Is ASND or ONC more profitable?

Do analysts prefer ASND or ONC?

Which has more volatility & risk, ASND or ONC?

Do insiders and institutionals have more ownership in ASND or ONC?

Summary

How does Ascendis Pharma A/S compare to Revolution Medicines?

Does the media prefer ASND or RVMD?

Which has stronger earnings & valuation, ASND or RVMD?

Is ASND or RVMD more profitable?

Do analysts prefer ASND or RVMD?

Which has more volatility & risk, ASND or RVMD?

Do insiders and institutionals have more ownership in ASND or RVMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASND vs. The Competition

Ascendis Pharma A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools